{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:23:19Z","timestamp":1785432199912,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12185-020-02845-6","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T08:03:12Z","timestamp":1583740992000},"page":"826-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-8008","authenticated-orcid":false,"given":"Yoshimichi","family":"Koutake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yasumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nagaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330\u201340.","journal-title":"N Engl J Med"},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2845_CR3","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500\u20135.","journal-title":"Cancer Res"},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658\u201361.","journal-title":"J Med Chem"},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1021\/jm060727j","volume":"49","author":"J Das","year":"2006","unstructured":"Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006;49:6819\u201332.","journal-title":"J Med Chem"},{"key":"2845_CR6","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/FTD.0b013e3181f4d9c5","volume":"32","author":"S Shayani","year":"2010","unstructured":"Shayani S. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Ther Drug Monit. 2010;32:680\u20137.","journal-title":"Ther Drug Monit"},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","volume":"49","author":"T Eley","year":"2009","unstructured":"Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol. 2009;49:700\u20139.","journal-title":"J Clin Pharmacol"},{"key":"2845_CR8","first-page":"481","volume":"50","author":"F Yagasaki","year":"2009","unstructured":"Yagasaki F, Niwa T, Abe A, Ishikawa M, Kato C, Ogura K, et al. Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki. 2009;50:481\u20137.","journal-title":"Rinsho Ketsueki"},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12185-008-0221-1","volume":"88","author":"A Abe","year":"2008","unstructured":"Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, et al. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol. 2008;88:471\u20135.","journal-title":"Int J Hematol"},{"key":"2845_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12185-015-1826-9","volume":"102","author":"H Nakamae","year":"2015","unstructured":"Nakamae H, Yoshida C, Miyata Y, Hidaka M, Uike N, Koga D, et al. A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits. Int J Hematol. 2015;102:304\u201311.","journal-title":"Int J Hematol"},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2845_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","volume":"69","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69:999\u20131004.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2845_CR13","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/bcp.12895","volume":"81","author":"E Pape","year":"2016","unstructured":"Pape E, Michel D, Scala-Bertola J, Schiestel T, Harl\u00e9 A, Bouchet S, et al. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol. 2016;81:1195\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"2845_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/CAD.0000000000000212","volume":"26","author":"H Kletzl","year":"2015","unstructured":"Kletzl H, Giraudon M, Ducray PS, Abt M, Hamilton M, Lum BL. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs. 2015;26:565\u201372.","journal-title":"Anticancer Drugs"},{"key":"2845_CR15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1177\/0091270009346061","volume":"50","author":"OQ Yin","year":"2010","unstructured":"Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol. 2010;50:960\u20137.","journal-title":"J Clin Pharmacol"},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-016-3087-6","volume":"78","author":"LH Lam","year":"2016","unstructured":"Lam LH, Capparelli EV, Kurzrock R. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol. 2016;78:427\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2845_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00280-012-1881-3","volume":"70","author":"OQ Yin","year":"2012","unstructured":"Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70:345\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2845_CR18","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol. 2013;5:85\u201397.","journal-title":"Clin Pharmacol"},{"key":"2845_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","volume":"72","author":"Y Ishida","year":"2016","unstructured":"Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K, et al. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol. 2016;72:185\u201393.","journal-title":"Eur J Clin Pharmacol"},{"key":"2845_CR20","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00277-018-3413-7","volume":"97","author":"S Osorio","year":"2018","unstructured":"Osorio S, Escudero-Vilaplana V, G\u00f3mez-Centuri\u00f3n I, P\u00e9rez-L\u00f3pez R, Ayala R, Vall-Llovera F, et al. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem? Ann Hematol. 2018;97:2089\u201398.","journal-title":"Ann Hematol"},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799\u2013807.","journal-title":"Int J Hematol"},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12185-012-1132-8","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka H, Nakashima S, Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol. 2012;96:308\u201319.","journal-title":"Int J Hematol"},{"key":"2845_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377\u201386.","journal-title":"Cancer"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3109\/10428194.2013.866663","volume":"55","author":"CT Chuah","year":"2014","unstructured":"Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma. 2014;55:2093\u2013100.","journal-title":"Leuk Lymphoma"},{"key":"2845_CR25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105:792\u2013804.","journal-title":"Int J Hematol"},{"key":"2845_CR26","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3892\/or.2016.5110","volume":"36","author":"M Hagihara","year":"2016","unstructured":"Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, et al. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: results of a D-First study. Oncol Rep. 2016;36:2976\u201382.","journal-title":"Oncol Rep"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","volume":"89","author":"S Paydas","year":"2014","unstructured":"Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014;89:242\u20137.","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02845-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02845-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:07:53Z","timestamp":1615252073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02845-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02845-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All use of patient data was in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}